Posts Archive

  • Bedaquiline treatment reaches patients in Uganda, Swaziland, Philippines, and Georgia January 24, 2017

    The Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program works with countries to adopt new medicines and regimens, such as bedaquiline for MDR-TB, using a systems strengthening approach that engages stakeholders, builds on existing systems or establishes new ones where appropriate, strengthens human resources via trainings, improves the ...

  • New TB Medicines & Regimens eCourse January 13, 2017

    Thanks to a bigger push for innovation as part of the End TB strategy, new medicines—bedaquiline (Sirturo™) and delamanid (Deltyba™)—are now available to treat MDR-TB and XDR-TB with a novel short-course regimen.

    However, countries and partners have been slow to use these drugs, and many health workers lack expertise in prescribing ...

  • SIAPS Launches Innovative Digital Health Tool in Georgia to Monitor Adverse Drug Reactions July 25, 2016

    In April 2015, the US Agency for International Development (USAID) and Janssen Therapeutics officially launched the bedaquiline donation initiative. As part of this initiative, Janssen committed to providing bedaquiline at no cost to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be ...

  • Bedaquiline Treatment Reaches 200 Patients in Georgia June 22, 2016

    Georgia is one of the first countries to benefit from the USAID‑Janssen Therapeutics bedaquiline (BDQ) donation program. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as ...

  • On the Market: Interviews on Bedaquiline Use April 13, 2016

    In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in ...